Charles River Labs Is the Better Medical Research Stock Buy in 2026 Over Bio-Rad

Industry
โดย Motley Fool·Read original
Summary · why it matters

Charles River Laboratories International is the better buy in 2026 compared to Bio-Rad Laboratories, according to a Motley Fool analysis. Charles River is further along in refocusing its business, with fiscal 2026 revenue projected at $3.9 billion and net income swinging back to profitability at $285 million, while Bio-Rad faces headwinds with expected sales of $2.57 billion and net income dropping to $225 million. Charles River also trades at a cheaper forward P/E of 16.6x versus Bio-Rad's 31.95x, despite Bio-Rad's higher current profitability and stronger balance sheet. Both companies are retooling for growth, but Charles River's progress and valuation give it the edge.

Impact on stocks 5

Biotech & Genomic Medicine± Mixed · 5 stocks
Charles River Laboratories
CRL
▲ PositiveCapitalrelevance

Article recommends Charles River as the better buy in 2026, highlighting projected revenue growth, return to profitability, and cheaper valuation.

Bio-Rad Laboratories Inc
BIO
▼ NegativeCapitalrelevance

Article compares Bio-Rad unfavorably to Charles River, citing lower projected revenue, declining net income, and higher forward P/E, making it a less attractive buy.

© 2026 MarketDXNews